Provided By GlobeNewswire
Last update: May 29, 2025
FOSTER CITY, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that members of senior management will be participating in the following upcoming investor conferences in June.
Read more at globenewswire.comNASDAQ:TERN (9/11/2025, 11:03:20 AM)
7.52
+0.05 (+0.67%)
Find more stocks in the Stock Screener